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Abstract
OBJECTIVE: The objective of this selective evidence based medicine review is to determine
whether or not far infrared therapy reduces the incidence of arteriovenous fistula (AVF)
malfunction in patients with renal disease undergoing hemodialysis.
STUDY DESIGN: Review of three primary randomized controlled trial studies published from
2007-2013.
DATA SOURCES: Three peer-reviewed randomized controlled trials studying the effectiveness
of far infrared therapy in the preservation of native arteriovenous fistula function in patients with
chronic kidney disease requiring hemodialysis. Data searches done in PubMed, CINAHL Plus
and EBSCOhost.
OUTCOMES MEASURED: Primary outcome measured was episodes of AVF malfunction due
to stenotic complication. After randomization, patient outcomes were monitored and recorded
over the span of 12 months to assess the effectiveness of far infrared therapy at preventing AVF
malfunction. AVF malfunction was defined as any stenosis-related change in the AVF resulting
in blood flow rate <200 ml/min (which requires surgical intervention or angioplasty). Infection,
aneurysm formation and steal syndrome were not considered stenosis-related.
RESULTS: All three articles demonstrated a lower incidence of AVF malfunction in patients
treated with far infrared therapy. The studies in question demonstrated zero incidence of any
adverse effect.
CONCLUSIONS: This review reinforces the author’s conclusions that FIR therapy, a noninvasive technique, is a useful modality for the prevention of complications requiring surgical
intervention and the preservation of arteriovenous fistulas. These conclusions should not be
extrapolated to patients with artificial AV grafts.
KEY WORDS: far infrared therapy; arteriovenous fistula; hemodialysis
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Introduction
Malfunction of vascular access is the most common cause of increased morbidity and
need for hospital admission in patients receiving hemodialysis.5 A technique capable of
extending the life of a vascular access port without complication would have potential to
improve the lives of the millions of people who require dialysis, as well as save the US an
estimated billion dollars in health care costs annually.4 This paper evaluates three recent RCTs
which address the efficacy of far-infrared therapy at reducing the incidence of stenosis related
arteriovenous fistula (AVF) malfunction.
AVF’s are commonly the first choice for vascular access patients with stage 3 or 4 kidney
disease because they are the access method with the lowest rates of infection and clotting
problems.5 The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
National Institutes of Health (NIH) estimates 398,861 ESRD patients were being treated with
some form of dialysis in 2009. Being a Physician Assistant in the ED, primary care, internal
medicine, surgery, nephrology and probably others will require knowledge of kidney dialysis and
the treatment mechanisms currently available to this patient population.
The estimated annual cost of vascular access related morbidity to the US is $1 billion
dollars.4 The exact number of healthcare visits each year is not known, but according to the NIH,
at the end of 2009, more than 871,000 people were being treated for ESRD, 398,861 of which
were receiving dialysis.
AVF malfunction remains the biggest obstacle to maintaining successful hemodialysis.
The most common source of complication is stenosis and/or thrombosis at the site of the AVF,
which alters flow state.5 Hemodialysis access fistulas alter fluid flow patterns within the vessel.
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Hemodialysis also requires frequent cannulation of the AVF. Over time, intimal hyperplasia
occurs secondary the frequent irritation by cannulation and in areas of turbulent blood flow,
which is generally at the created anastomosis. Hyperplasia results in decreased patency and
further alteration of flow pattern. Decreased flow through the area can then result in thrombosis
and eventual occlusion. A specific flow rate (>200 ml/min) is required for adequate
hemodialysis. These intravascular conditions synergistically create an environment prone to
complication. It is important to prevent complications interfering with hemodialysis for the
obvious reason that without adequate hemodialysis access, patients with end stage renal disease
cannot receive the treatment allowing for their survival and must shift to alternate forms of
dialysis with greater inherent risk of infection.
There is no currently accepted or widely used therapy which prevents the formation of
intimal wall lesions and subsequent complications at the AVF site.6 Problems arising from
thrombosis and stenosis of the AVF are dealt with as they arise, which typically involves either
stent placement or angioplasty depending on the preference of the physician.6
Far infrared (FIR) therapy is a non-invasive technique that is being proposed as a means
to prevent complications at the AVF site and thus sustain AVF patency. It entails the
administration of electromagnetic wavelengths via an external transmitter. Treatment involves
placing a radiator device above the surface of the AVF for a period of minutes several times per
week. Far infrared therapy can be done while undergoing hemodialysis treatments. Intervention
specifics are listed in Table 1.
Authors suggest administration of FIR therapy improves endothelial function and
prevents pathogenic changes associated with increased risk of AVF malfunction. Specifically,
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the therapy has vasodilatory effects, prevents intimal hyperplasia, decreases oxidative stress and
suppresses inflammation.2 Thus, a therapy such as this could reduce morbidity and cost
associated with AVF complications.
Objective
The objective of this selective EBM review is to determine whether or not far infrared
therapy is an efficacious way to reduce the incidence of stenosis-related AVF malfunction in
patients receiving hemodialysis.
Methods
Articles designated for this selective evidence based medicine review have proven to be
adequate to investigate the objective. The articles consist of three randomized control trials. The
articles were selected using the key words: far infrared therapy; arteriovenous fistula (AVF);
hemodialysis. The author of this selective EBM review, Parker Barrett, conducted the research in
Cochrane, PubMed, CINAHL Plus and EBSCOhost in January 2014. All articles were published
in Chinese and English languages in peer-reviewed journals. Articles were chosen if they
assessed patient oriented outcomes and included patients with CKD requiring hemodialysis,
patients with native AVF, and population age greater than 18. Articles were excluded if they
were review articles, non-patient oriented outcomes, and population age less than 18. Statistics
were reported using p-values, relative risk reduction (RRR), absolute risk reduction (ARR),
numbers needed to treat (NNT). P-values less than 5% were considered statistically significant.
In Lin et al. (2013)3, a prospective randomized controlled trial, inclusion criteria were
patients 18-80 years old with CKD and eGFR = 5-20 mL/min/1.73m2, recently created upper
extremity venous-to-arterial anastomosis and patients not anticipated to receive dialysis or renal
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transplant within three months. FIR therapy was initiated 2 days postoperative anastomosis
creation 3 times weekly for 12 months. Before starting hemodialysis, 40 minutes of FIR was
done 3 times weekly at home or clinic. After beginning dialysis, FIR therapy was done for 40
minutes 3 times weekly during hemodialysis at clinic. External far infrared therapy (via FIR
emitter) set at a height of 25 cm above the surface of the AVF.
In Lin et al. (2007)1 and Lin et al. (2013)2, both prospective randomized controlled trials,
the inclusion criteria were identical and as follows: patients receiving 4 hours hemodialysis 3
times weekly for at least 6 months via upper extremity venous-to-arterial anastomosis, in patients
without interventions within the past 3 months. FIR therapy was done for 40 minutes 3 times
weekly during hemodialysis at clinic for 12 months. External far infrared therapy (via FIR
emitter) set at a height of 25 cm above the surface of the AVF.
The demographics of the studies included are demonstrated in Table 1. All three studies
used untreated control groups for comparison. Patients were censored (withdrawal in Table 1) for
reasons other than AVF malfunction, i.e. those with renal transplant, death with a functioning
access, shift to peritoneal dialysis for reason other than stenotic complication, loss to follow up
or non-stenotic complications (infection, aneurysm, steal syndrome).
Randomization accounted for differences in patient comorbidities. All three studies
compared clinical characteristics of FIR treated and control groups, including age, gender, the
length of time since AVF creation, history of AVF malfunction, and prevalence of hypertension
and diabetes. Statistical analysis showed no significant difference between the two groups in all
cases (p-values > 5%).
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Outcomes Measured
Outcomes measured included number of episodes of AVF malfunction secondary to
stenotic complication. After randomization, patient outcomes were monitored and recorded over
the span of 12 months to assess the effectiveness of FIR therapy at reducing the incidence of
stenotic AVF malfunction. AVF malfunction was defined as any stenosis-related change in the
AVF resulting in blood flow rate <200 ml/min (which requires surgical intervention or
angioplasty). Infection, aneurysm formation and steal syndrome were not considered stenosisrelated.
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Table 1: Demographics and Characteristics of included studies
Study Type
Lin,
20071

RCT

# Pts Age
(yrs)
145
18-80

Lin,
20132

RCT

280

18-80

Lin,
20133

RCT

122

18-80

Inclusion criteria

(i) receiving 4 h of
maintenance HD
therapy 3 times weekly
for at least 6 months
(ii) using a native AVF
as the present vascular
access
for >6 months, without
interventions within last
3 months
(iii) creation of AVF by
venous-to-arterial
anastomosis in upper
extremity
(i) CKD and eGFR = 520 mL/min/1.73m2
(ii) Recently created
upper extremity venousto-arterial anastomosis
(iii) Patients not
anticipated to receive
dialysis or renal
transplant within three
months

(i) receiving 4 h of
maintenance HD
therapy 3 times weekly
for at least 6 months
(ii) using a native AVF
as the present vascular
access
for >6 months, without
interventions within last
3 months
(iii) creation of AVF by
venous-to-arterial
anastomosis in upper
extremity

Exclusion W/D
Criteria
AV graft as 18
the first
vascular
access.

Intervention

AV graft as 34
the first
vascular
access.

Far-infrared radiation
via emitter set at a
height of 25 cm
above the surface of
the AVF for 40 min
during hemodialysis
3 times per week.

AV graft as 14
the first
vascular
access.

Far-infrared radiation
via emitter set at a
height of 25 cm
above the surface of
the AVF for 40 min
during 3 times per
week (during
hemodialysis once it
has begun)

Far-infrared radiation
via emitter set at a
height of 25 cm
above the surface of
the AVF for 40 min
during hemodialysis
3 times per week.
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Results
All three studies compared FIR therapy to untreated control groups and thus data
breakdown was experimental vs. untreated. All relevant data was presented in dichotomous
form, easily assessed for treatment effect on complication incidence. Figure 1 depicts the raw
incidence of stenosis-related AVF malfunction over the span of 12 months in all three studies.
All three studies showed zero incidence of adverse effect, such as skin burn or allergy to therapy.

Figure 1: Incidence of AVF Malfunction within 12 Months
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Lin et al., 20071 demonstrated a statistically significant reduction in AVF malfunction
incidence (P<0.01), with 12.5% (9/63) of FIR treated patients and 30.1% (22/64) of untreated
patients developing new AVF malfunction. Absolute risk reduction was calculated as 17.6%,
while the NNT was calculated as 6 (Table 2). Relative risk reduction was found to be 58.5%.
This suggests a 17.6% reduction in stenotic complication incidence and that 6 patients must be
treated with FIR therapy to prevent one AVF malfunction. The relative risk reduction indicates a
58.5% reduced risk of stenotic malfunction in FIR treated patients.
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Lin et al. 20132 observed a statistically significant reduction in stenotic AVF malfunction
incidence, with 12.6% (15/119) of FIR treated patients and 27.5% (33/120) of untreated patients
developing new AVF malfunction (p = 0.004). Absolute risk reduction was calculated as 14.9%,
while the NNT was calculated as 7 (Table 2). Relative risk reduction was found to be 54.2%.
This suggests a 14.9% reduction in stenotic complication incidence and that 7 patients must be
treated with FIR therapy to prevent one AVF malfunction. The relative risk reduction indicates a
54.2% reduced risk of stenotic malfunction in FIR treated patients.
Table 2: Efficacy of FIR Therapy in Reducing the Incidence of AVF Malfunction
p-value
RRR
ARR
NNT
1
<0.01
0.585
0.176
6
Lin et al., 2007
0.004
0.542
0.149
7
Lin et al. 20132
3
0.02
0.586
0.170
6
Lin et al. 2013

Lin et al. 20133 observed a statistically significant reduction in stenotic AVF malfunction
incidence, with 12% (7/60) of FIR treated patients and 29 % (18/62) of untreated patients
developing new AVF malfunction (p = 0.02). Absolute risk reduction was calculated as 17.0%,
while the NNT was calculated as 6 (Table 2). Relative risk reduction was found to be 58.6%.
This suggests a 17.0% reduction in stenotic complication incidence and that 6 patients must be
treated with FIR therapy to prevent one AVF malfunction. The relative risk reduction indicates a
58.6% reduced risk of stenotic malfunction in FIR treated patients.
Discussion
Native arteriovenous fistulae are the most superior form of vascular access for
hemodialysis, due to lower infection rates and greater durability.5 AVF failure necessitates other
access modalities with higher risk for infection and subsequent sepsis, making preservation of
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the native fistula of the utmost importance.5 Far infrared therapy is a non-invasive technique
which could potentially be a useful modality for the prevention of thrombotic complications
requiring percutaneous or surgical declotting and the preservation of native arteriovenous
fistulas.
The precision of statistical values across the three studies (Table 2), consistent study
parameters, and adequate sample sizes speak well in support of the authors conclusions.
Few of the current approaches to preventing AVF thrombosis are supported by statistical
efficacy. Neither antiplatelet therapy nor systemic anticoagulation has proven to be effective in
thrombosis prevention.6 Avoidance of unnecessary venipuncture and fish oil (4 g per day) are the
only current measures routinely recommended for prevention of AVF thrombosis.6 Stenosis is
generally addressed as it becomes apparent with percutaneous angioplasty. Considering the low
number of currently available preventative techniques and the lack of apparent adverse effects,
FIR therapy could prove to be a beneficial adjunct to hemodialysis.
Sample sizes were adequate for analysis of statistical significance. Compliance was 100%
due to the fact that FIR treatment was tied to hemodialysis. Study limitations include the lack
blinding in the control group. Blinding for future studies would require the use of a sham device
similar in appearance to the FIR transducer. Despite lack of sham, results suggest efficacy
beyond that of the placebo effect.
The most concerning limitation of the results listed above is the singular institution and
authors responsible for the conduction of all three studies. Lin and colleagues of the Yang-Ming
University of Taiwan have put forth excellent data, but reproduction by unaffiliated colleagues is
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necessary. Also, all study participants were native to the region, so investigation as to whether
ethnicity has any effect on treatment outcome is desirable.
Little investigation has been done into the cost of making far infrared therapy available at
hemodialysis facilities, or any form of cost-benefit analysis for that matter. A formal
investigation into the annual cost of stenotic AVF malfunction vs. the savings allowed for by
making far infrared therapy available on a large scale is needed.
Conclusion
The data assessed in this EBM review suggest far infrared therapy does significantly
reduce the incidence of arteriovenous fistula malfunction in patients undergoing hemodialysis.
Patients receiving FIR therapy required fewer interventions in all three studies. Further research
is needed to determine if the reduction of complication incidence can be extended to patients
with graft AVF ports. Reproduction of effects by another group of researchers would also be
desirable.
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